WO1999028344A2 - Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment - Google Patents
Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment Download PDFInfo
- Publication number
- WO1999028344A2 WO1999028344A2 PCT/EP1998/007714 EP9807714W WO9928344A2 WO 1999028344 A2 WO1999028344 A2 WO 1999028344A2 EP 9807714 W EP9807714 W EP 9807714W WO 9928344 A2 WO9928344 A2 WO 9928344A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- peptides
- rheumatoid arthritis
- antibodies
- antibody
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 271
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 170
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 101
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 title claims abstract description 54
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 235000013477 citrulline Nutrition 0.000 title claims abstract description 33
- 229960002173 citrulline Drugs 0.000 title claims abstract description 33
- 238000003745 diagnosis Methods 0.000 title abstract description 16
- 238000011282 treatment Methods 0.000 title abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000002163 immunogen Effects 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 101710088660 Filaggrin Proteins 0.000 claims description 67
- 102100028314 Filaggrin Human genes 0.000 claims description 67
- 235000018102 proteins Nutrition 0.000 claims description 66
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 35
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 230000003302 anti-idiotype Effects 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 26
- 102000012411 Intermediate Filament Proteins Human genes 0.000 claims description 23
- 108010061998 Intermediate Filament Proteins Proteins 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 14
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 238000003786 synthesis reaction Methods 0.000 claims description 12
- 238000009007 Diagnostic Kit Methods 0.000 claims description 10
- 102000013127 Vimentin Human genes 0.000 claims description 10
- 108010065472 Vimentin Proteins 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 210000005048 vimentin Anatomy 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 102000001235 protein arginine deiminase Human genes 0.000 claims description 7
- 108060006632 protein arginine deiminase Proteins 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 238000004166 bioassay Methods 0.000 claims description 6
- 241000701447 unidentified baculovirus Species 0.000 claims description 6
- 102100023129 Keratin, type I cytoskeletal 9 Human genes 0.000 claims description 5
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 238000001212 derivatisation Methods 0.000 claims description 4
- 230000002637 immunotoxin Effects 0.000 claims description 4
- 239000002596 immunotoxin Substances 0.000 claims description 4
- 231100000608 immunotoxin Toxicity 0.000 claims description 4
- 229940051026 immunotoxin Drugs 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 101710194922 Keratin, type II cytoskeletal 1 Proteins 0.000 claims description 3
- 108010070585 Keratin-9 Proteins 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000037029 cross reaction Effects 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 230000005859 cell recognition Effects 0.000 claims description 2
- 230000004046 hyporesponsiveness Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 230000009257 reactivity Effects 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 235000009697 arginine Nutrition 0.000 description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000004475 Arginine Substances 0.000 description 9
- 241000206602 Eukaryota Species 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- -1 for example Chemical class 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 108700041153 Filaggrin Proteins Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000003278 mimic effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 101000917159 Homo sapiens Filaggrin Proteins 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 235000014304 histidine Nutrition 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000003169 placental effect Effects 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229920004898 Triton X-705 Polymers 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 4
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 230000003456 anti-perinuclear Effects 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 102100029968 Calreticulin Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001622557 Hesperia Species 0.000 description 2
- 101001050274 Homo sapiens Keratin, type I cytoskeletal 9 Proteins 0.000 description 2
- 101001046960 Homo sapiens Keratin, type II cytoskeletal 1 Proteins 0.000 description 2
- 101000803403 Homo sapiens Vimentin Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000532784 Thelia <leafhopper> Species 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 102000057393 human VIM Human genes 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108010075526 keratohyalin Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000006656 viral protein synthesis Effects 0.000 description 2
- 230000006490 viral transcription Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical group C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- PQMRRAQXKWFYQN-UHFFFAOYSA-N 1-phenyl-2-sulfanylideneimidazolidin-4-one Chemical compound S=C1NC(=O)CN1C1=CC=CC=C1 PQMRRAQXKWFYQN-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- JSLGXODUIAFWCF-WDSKDSINSA-N Arg-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O JSLGXODUIAFWCF-WDSKDSINSA-N 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 description 1
- KRBMQYPTDYSENE-BQBZGAKWSA-N His-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 KRBMQYPTDYSENE-BQBZGAKWSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 108010036939 Occlusion Body Matrix Proteins Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- KNYPNEYICHHLQL-ACRUOGEOSA-N Phe-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 KNYPNEYICHHLQL-ACRUOGEOSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 108010035746 Pregnancy Proteins Proteins 0.000 description 1
- 102000008217 Pregnancy Proteins Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 1
- CKHWEVXPLJBEOZ-VQVTYTSYSA-N Thr-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O CKHWEVXPLJBEOZ-VQVTYTSYSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100032250 Trichohyalin Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- CGWAPUBOXJWXMS-HOTGVXAUSA-N Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 CGWAPUBOXJWXMS-HOTGVXAUSA-N 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N Valylglycine Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical class N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000321 buccal mucosa cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 108091006007 citrullinated proteins Proteins 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 125000001965 gamma-lactamyl group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 108010031667 trichohyalin Proteins 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to certain peptides containing citrulline and that constitute immunogenic determinants of antibodies present in sera from patients with rheumatoid arthritis and wherein the presence of at least one citrulline is a prerequisite for reacting with said antibodies.
- the invention also relates to the a method of producing said peptides and the use of said peptides for diagnosis and treatment of rheumatoid arthritis and related diseases.
- the present invention also relates to new filaggrin alleles.
- RA Rheumatoid arthritis
- RA has all the features of an autoimmune disease, including the presence of a variety of autoantibodies in patients' sera and the capacity to induce illness by transfer of pathogenic T cells in animal models.
- the classification of the disease can be challenged on the grounds that borderline forms are very common; furthermore inflammation of the joints is not only restricted to RA, but occurs also in other non-autoimmune diseases such as osteoarthritis, reactive arthritis and gout.
- RA rheumatologists
- the diagnosis of RA is initially based on clinical manifestations. Serological support for such a diagnosis is not very well established and is based mainly on the presence of rheumatoid factors (RF).
- RF rheumatoid factors
- RA patients are RF seronegative, while on the other hand, RF is also present in other rheumatic diseases including Sj ⁇ gren's syndrome and systemic lupus erythematosus, in some chronic bacterial and acute viral infections, in certain parasitic diseases and chronic inflammatory diseases, and has furthermore been demonstrated in control sera from healthy persons (Waller et al., 1 964; Chen et al., 1 987). This rather low specificity of RF necessitates additional testing for a second RA-specific antibody.
- APF antiperinuclear factor
- AKA antikeratin antibodies
- a second specificity found in sera of RA patients are the AKA, autoantibodies that were first described by Young et al. ( 1 979) and that give rise to a fluorescent staining pattern with the keratinized layer of rat oesophageal epithelium.
- the antibodies were infered to be antikeratin antibodies on the disputable ground that cytokeratins constitute the major component of the stratum corneum.
- the human epidermal protein filaggrin was recently identified with convincing evidence as one of the major targets for reactivity with AKA and APF autoantibodies (Simon et al., 1 993; Sebbag et al., 1 995) .
- the neutral/acidic form of human filaggrin was demonstrated to react with 75% of a group of 48 RA sera in Western blot (Simon et al., 1 993). More recent data (Vincent et al., 1 997) showed a diagnostic sensitivity of more than 50% for antifilaggrin detection with a corresponding specificity of 95% within a group of 492 sera which included 279 RA sera.
- Profilaggrin the precursor of filaggrin is a histidine-rich, insoluble protein of ⁇ 400-kDa. It consists of 1 0-1 2 filaggrin repeats of 324 amino acids that are separated by a heptamer linker sequence. The highly phosphorylated polyprotein is stored in the keratohyalin granules of the granular layer of the epidermis. Upon terminal differentiation of these cells, profilaggrin is dephosphorylated and proteolytically processed by excision of the linker into functional basic filaggrin molecules of 37-kDa (Resing et al., 1 989; 1 993; Gan et al., 1 990).
- these units are involved in the aggregation of keratin intermediate filaments, facilitating formation of intermolecular disulfide bonds and yielding the intracellular fibrous matrix of the cornified cells (Dale et al., 1 978; Lynley and Dale,
- tandemly arranged filaggrin units are highly polymorphic: there exists a considerable variation in amino acid sequence across individuals and also between the different filaggrin molecules of one person, where up to 1 5% of differences have been noted (McKinley-Grant et al., 1 989; Gan et al., 1 990; Markova et al.,
- Another aim of the present invention is to provide methods for obtaining said peptides.
- Another aim of the present invention is to provide methods of raising antibodies specifically reactive with said peptides.
- Another aim of the present invention is to provide methods of raising anti- idiotype antibodies specifically reactive with the afore mentioned antibodies, thereby mimicking said peptides.
- Another aim of the present invention is to provide a pharmaceutical composition comprising these peptides, for therapy or diagnosis.
- Another aim of the present invention is to provide a diagnostic kit for rheumatoid arthritis.
- Another aim of the present invention is to provide a modulator, a composition containing a modulator, or a combination of modulators identified by the bioassay as described above.
- the immunodominant epitopes of filaggrin were identified, which all contained the unusual amino acid citrulline. Synthetic peptides were generated and proved useful for diagnosis of RA. By probing human rheumatoid arthritis sera onto 2-D blots containing placental extracts another specificity was found. The immunoreactive spots were identified and peptides from human vimentin, cytokeratin 1 and cytokeratin 9 were retrieved in addition to other non-identified peptides. These proteins all belong to the same family of intermediate filament proteins.
- the present invention relates to peptides containing less than 50 amino acids, comprising fragments of a filaggrin variant or fragments of intermediate filament proteins, wherein at least one arginine is substituted by citrulline, and that are able to react with antibodies, wherein the presence of said citrulline is crucial for reaction between said peptide and said antibodies, and wherein said antibodies are present in sera from patients with rheumatoid arthritis.
- the present invention relates to peptides as presented in claim 2.
- the present invention also relates to a peptide and/or chemical structure comprising any of the above mentioned peptides, fused to a linker molecule.
- the present invention also relates to peptides comprising and/or consisting of tandem repeats of at least two of any of the above mentioned peptides, or branched peptides that comprises at least one of the above mentioned peptides.
- the present invention also relates to a method for producing any of the above mentioned peptides, by classical chemical synthesis, wherein at least one arginine residue is substituted by citrulline, at certain steps during the chemical synthesis.
- the present invention also relates to a method for producing any of the above mentioned peptides, wherein the primary amino acid sequence is produced by classical chemical synthesis, and wherein said arginine residue is derivatized towards citrulline after chemical synthesis by incubation with peptidylarginine deiminase.
- the present invention also relates to a method for producing any of the above mentioned peptides comprising the following steps: (i) transforming an appropriate cellular host with a recombinant vector in which a polynucleic acid is inserted comprising the sequence that codes for said peptide under the control of the appropriate regulatory elements such that said peptide or a protein comprising said peptide is expressed and/or secreted, (ii) culturing said transformed cellular host under conditions allowing expression of said protein or peptide and allowing a partial or optimal derivatization of said arginines present in said peptide, towards citrulline residues, and (iii) harvesting said peptide.
- the present invention also relates to a method for producing any of the above mentioned peptides comprising the following steps: (i) transforming an appropriate cellular host with a recombinant vector in which a polynucleic acid is inserted comprising the sequence that codes for said peptide under the control of the appropriate regulatory elements, such that said peptide or a protein comprising said peptide is expressed and/or secreted, (ii) culturing said transformed cellular host under conditions allowing expression of said protein or said peptide, (iii) harvesting said protein or said peptide, and (iv) derivatizing arginine residues of said protein or said peptide towards citrulline residues.
- the present invention also relates to any of the above mentioned methods, wherein said host cell is a bacterial host or yeast or any other eukaryotic host cell which is preferably transformed with a recombinant baculovirus.
- the present invention also relates to an antibody being specifically reactive with said peptides or intermediate filament proteins that contain citrulline residues, and with said antibody being preferably a monoclonal antibody.
- the present invention also relates to an anti-idiotype antibody raised upon immunization with any antibody as defined above, with said anti- idiotype antibody being specifically reactive with said antibody, thereby mimicking any of the above mentioned peptides, and with said antibody being preferably a monoclonal antibody.
- the present invention also relates to an immunotoxin molecule comprising and/or consisting of a cell recognition molecule being a peptide as defined above, or an antibody as defined above, covalently bound to a toxin molecule or active fragment thereof.
- the present invention relates to any of the above mentioned peptides or antibodies or immunotoxine molecules or intermediate filament proteins or a composition thereof for use as a medicament.
- Said use can have the purpose of a medicament for treatment or of a diagnosticum for rheumatoid arthritis.
- the present invention also relates to a treatment for autoimmune diseases by inducing a state of systemic hyporesponsiveness to the auto- antigen after oral administration of any of the above mentioned peptides or antibodies or immunotoxine molecules or intermediate filament proteins or a composition thereof, thereby preventing the pathogenic production of anti-self antibodies.
- the present invention also relates to a diagnostic kit for use in detecting rheumatoid arthritis, wherein said kit comprises at least one of the above mentioned peptides or proteins or antibodies, and with said peptide, proteins or antibody being possibly bound to a solid support. More preferably said kit is comprising a range of said peptides or said antibodies, possibly in combination with other epitopes that can characterize auto-immune disease, wherein said peptides, proteins and/or antibodies are attached to specific locations on a solid substrate. More preferably said solid support is a membrane strip and said polypeptides are coupled to the membrane in the form of parallel lines.
- the present invention relates to those peptide fragments of natural filaggrin variants that react with antibodies characteristically present in sera of patients with rheumatoid arthritis and that are further characterized by a post-translational modification, more preferably a derivatization of arginine towards citrulline.
- the presence of at least one citrulline residue is a prerequisite for recognition by antibodies that are specifically present in sera of patients with rheumatoid arthritis.
- Synthetic peptides were generated wherein arginine residues were substituted by citrulline, thus mimicking the epitopes of natural filaggrin variants. These peptides proved useful for diagnosis of rheumatoid arthritis.
- the present invention relates to peptides which immunologically mimic the immunogenic determinants of self proteins recognized by the immune system in patients suffering from rheumatoid arthritis.
- citrulline can be sufficient for specific recognition by some antibodies present in sera of patients with rheumatoid arthritis.
- 'peptide' refers to a polymer of amino acids and does not refer to a specific length of the product; thus, oligopeptides, polypeptides and proteins are included within the definition of 'peptide'. This term also does not exclude post-expression modifications of the peptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, peptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids, PNA, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
- peptide containing less than 50 amino acids this should be interpreted in a broad sense, as a means of circumscribing an essentially truncated version of the entire immunoreactive protein that still comprises the highly reactive domain characterized by the presence of citrulline residues.
- These peptides have a length of preferably 40, 30, 25, 20 or less amino acids.
- 'immunogenic determinant is meant, those chemical groupings comprising a primary amino acid sequence, and secondary modifications of the amino acid residues in a certain three-dimensional arrangement, that together determine the specific reactivity of the entire antigen for a raised antibody.
- Such antibody can also recognize different chemical groupings, which are then termed to 'immunologically mimic' the immunogenic determinant.
- crossreaction also refers to the reaction of one antigen with antibodies developed against another antigen or against antibodies that are found in sera from patients with different diseases.
- the present invention relates to those peptides or proteins that contain citrulline residues, wherein the presence of said citrulline residues is crucial for high-affinity interaction with antibodies that are characteristically present in sera of patients with rheumatoid arthritis.
- the present invention relates to a peptide that is characterized by the amino acid sequence HSASQDGQDT1RGHPGSS or,
- the present invention relates to peptides comprising a sequence of less than 50 amino acids of any variant of vimentin, cytokeratin 1 or cytokeratin 9, comprising at least one citrulline residue, and wherein the presence of said citrulline is crucial for reacting with antibodies that are present in sera from patients with rheumatoid arthritis.
- the present invention also relates to molecular structures in which at least part represents a peptide or antibody as defined above.
- Such molecular structures can result from fusion of peptides of the present invention with peptides and/or proteins and/or other molecules that are further characterized in that they -specifically interact with other peptides and/or proteins and/or molecular structures, enabling tagging and/or binding of the fused polypeptide and/or protein to specific tissue- or cell types or that allow for purification of said molecular structures due to the presence of for instance 4, or 5 or 6 consecutive histidine residues, or
- cytotoxic to T-cells and/or B-cells such as cholera toxin, or -allow for labelling by means of a radioactive or fluorescent or immunogold or enzymatic marker.
- tandem repeats or branched peptides of the antigens can increase the amount of immobilized antigens presented to the antibodies and thereby increase the sensitivity of the assay.
- the sensitivity can be increased exponentially when the immobilized antigens are used together with a specific concentration of such antigens in a soluble form, thereby inducing the formation of crosslinked antigen- immunoprecipitates.
- a second advantage relates to therapy.
- the deposition of self- antigen autoimmune complexes in various tissues is an important step towards the acquisition of a pathological condition. It is generally accepted that the main cause of said deposition is the insufficient blood clearance by the liver of the antigen- immune complexes due to the small size of said complexes. Administration of tandem repeats or branched forms of said peptides could increase the size of the formed antigen-immune complexes, and thereby increases the clearance and thus decreases the deposition of said complexes.
- the present invention also relates to circularized forms of said peptides, the advantage being well known in the art, and relating to an increased affinity of a conformationally constraint peptide as compared with the more randomly coiled forms of linear peptides.
- peptides In order to accommodate for eventual negative characteristics of the claimed peptides, such as rapid degradation, solubility, cytotoxic effects and so on, the skilled person will be able to design conservative as well as non-conservative amino acid substitutions, or substitutions with non-natural amino acids, etc... These will generally account for less than 35 percent of a specific sequence.
- Such peptides also include peptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. It may be desirable in cases where the filaggrin peptides of the present invention are highly polymorphic, to vary one or more of the amino acids so as to better mimic the different epitopes, or as recognized by antibodies in sera from patients with rheumatoid arthritis.
- the present invention also relates to the new allelic variants that were isolated , cloned and sequenced, characterized by the DNA sequence as presented in figure 6 and the amino acid sequence as presented in figure 2.
- the present invention also relates to any analogs of the peptides of the present invention.
- analog as used throughout the specification or claims to describe the proteins or peptides of the present invention, includes any protein or peptide having an amino acid residue sequence substantially identical to a sequence specifically shown herein in which one or more residues have been conservatively substituted with a biologically equivalent residue.
- conservative substitutions include the substitution of hydrophobic residue such as isoleucine, valine, leucine or methionine for another, the substitution of one hydrophilic residue for another such as between arginine and lysine, between glutamine and asparagines, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another. Examples of allowable mutations according to the present invention can be found in Table 1 .
- “Chemical derivative” refers to a protein or peptide having one or more residues chemically derivatized by reaction of a functional side group or peptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
- Examples of such derivatized molecules include but are not limited to, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloracetyl groups or formyl groups.
- Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides.
- Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives.
- the imidazole nitrogen of histidine may be derivatized to form N-imbenzylhistidine.
- chemical derivatives are those proteins or peptides which contain one or more naturally- occurring amino acid derivatives of the twenty standard amino acids. For examples : 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine.
- the peptides of the present invention also include any protein or peptide having one or more additions and/or deletions or residues relative to the sequence of a peptide whose sequence is shown herein, as long as the peptide is biologically equivalent to the proteins or peptides of the invention.
- Amino acids Synonymous groups
- linker arm by which the peptide can conveniently be attached to a carrier.
- the linker arm will be at least one amino acid and may be as many as 60 amino acids but will most frequently be
- the peptides of the invention can be prepared by classical chemical synthesis.
- the synthesis can be carried out in homogeneous solution or in solid phase.
- the synthesis technique in homogeneous solution which can be used is the one described by Houbenweyl in the book entitled “Methode der organischen chemie” (Method of organic chemistry) edited by E. Wunsh, vol. 1 5-1 et II. THIEME, Stuttgart 1 974.
- the polypeptides of the invention can also be prepared in solid phase according to the methods described by Atherton and Shepard in their book entitled “Solid phase peptide synthesis” (IRL Press, Oxford, 1 989).
- the forms of the claimed peptides can be obtained by substituting the citrulline residues for the original arginine derivatives during the classical chemical synthesis, or by contacting the peptides after synthesis with a peptidylarginine deiminase of any eukaryotic origin.
- polypeptides according to this invention can also be prepared by means of recombinant DNA techniques as described by Maniatis et al., Molecular Cloning: A Laboratory Manual, New York, Cold Spring Harbor Laboratory, 1 982) by insertion of a polynucleic acid sequence encoding the claimed peptides or part of the claimed peptides in an appropriate vector and transforming a suitable host with said vector.
- This recombinant expression vector comprises a polynucleic acid or a part thereof as defined above, operably linked to prokaryotic, eukaryotic or viral transcription and translation control elements.
- this sequence can be operably linked with sequences that allow for secretion of the claimed peptides.
- the term 'vector' may comprise a plasmid, a cosmid, a phage or a virus or a transgenic organism. Particularly useful may be BCG or adenoviral vectors, as well as avipox recombinant viruses.
- the recombinant peptides can be derivatized in vitro, by contacting the expressed and/or secreted peptides with a of any eukaryotic origin, or in vivo by choosing the appropriate host, like yeast, or any eukaryotic cell, and more preferably by using the baculovirus transformation system, or by coexpressing said peptides with recombinant peptidylarginine deiminase.
- any of the known purification methods for recombinant peptides can be used for the production of the recombinant peptides of the present invention.
- the present invention also relates to a recombinant expression vector comprising a polynucleic acid or a part thereof as defined above, operably linked to prokaryotic, eukaryotic or viral transcription and translation control elements.
- said recombinant vector will comprise a vector sequence, an appropriate prokaryotic, eukaryotic or viral promoter sequence followed by a nucleotide sequence encoding a peptide as defined above, with said recombinant vector allowing the expression and/or secretion of any one of the polypeptides as defined above in a prokaryotic, or eukaryotic host or in living mammals when injected as naked DNA.
- any of the known purification methods for recombinant proteins may be used for the production of the recombinant polypeptides of the present invention.
- vector may comprise a plasmid, a cosmid, a phage, or a virus or a transgenic animal. Particularly useful for vaccine development may be BCG or adenoviral vectors, as well as avipox recombinant viruses.
- the present invention also relates to a method for the production of a recombinant polypeptide as defined above, comprising: transformation of an appropriate cellular host with a recombinant vector, in which a polynucleic acid or a part thereof according to as defined above has been inserted under the control of appropriate regulatory elements, culturing said transformed cellular host under conditions enabling the expression and/or secretion of said insert, and, harvesting said polypeptide.
- recombinantly expressed used within the context of the present invention refers to the fact that the proteins of the present invention are produced by recombinant expression methods be it in prokaryotes, or lower or higher eukaryotes as discussed in detail below.
- lower eukaryote refers to host cells such as yeast, fungi and the like. Lower eukaryotes are generally (but not necessarily) unicellular. Preferred lower eukaryotes are yeasts, particularly species within Saccharomyces. Schizosaccharomvces, Kluveromyces, Pichia (e.g. Pichia pastoris) , Hansenula (e.g.
- Saccharomyces cerevisiae, S_. carlsbergensis and K. lactis are the most commonly used yeast hosts, and are convenient fungal hosts.
- prokaryotes refers to hosts such as E.coli. Lactobacillus. Lactococcus, Salmonella, Streptococcus, Bacillus subtilis or Streptomyces. Also these hosts are contemplated within the present invention.
- higher eukaryote refers to host cells derived from higher animals, such as mammals, reptiles, insects, and the like.
- Presently preferred higher eukaryote host cells are derived from Chinese hamster (e.g. CHO), monkey (e.g. COS and Vero cells), baby hamster kidney (BHK), pig kidney (PK1 5), rabbit kidney
- the host cells may be provided in suspension or flask cultures, tissue cultures, organ cultures and the like. Alternatively the host cells may also be transgenic animals.
- polynucleotide or “nucleic acid” intends a polynucleotide or nucleic acid of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation : ( 1 ) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.
- recombinant host cells refer to cells which can be or have been, used as recipients for a recombinant vector or other transfer polynucleotide, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
- telome any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.
- vector is a replicon further comprising sequences providing replication and/or expression of a desired open reading frame.
- control sequence refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated.
- control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, splicing sites and terminators; in eukaryotes, generally, such control sequences include promoters, splicing sites, terminators and, in some instances, enhancers.
- control sequences is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion.
- promoter is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene.
- operably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
- a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
- the polynucleic acids encoding the peptides of the present invention and inserted into the vector sequence may be attached to a signal sequence.
- Said signal sequence may be that from any source, e.g. the IgG or tissue plasminogen activator (tpa) leader sequence for expression in mammalian cells, or the ⁇ -mating factor sequence for expression into yeast cells.
- a variety of vectors may be used to obtain the peptides of the present invention.
- Lower eukaryotes such as yeasts and glycosylation mutant strains are typically transformed with plasmids, or are transformed with a recombinant virus.
- the vectors may replicate within the host independently, or may integrate into the host cell genome.
- Higher eukaryotes may be transformed with vectors, or may be infected with a recombinant virus, for example a recombinant vaccinia virus.
- Techniques and vectors for the insertion of foreign DNA into vaccinia virus are well known in the art, and utilize, for example homologous recombination.
- a wide variety of viral promoter sequences, possibly terminator sequences and poly(A)-addition sequences, possibly enhancer sequences and possibly amplification sequences, all required for the mammalian expression, are available in the art.
- Vaccinia is particularly preferred since vaccinia halts the expression of host cell proteins.
- Vaccinia is also very much preferred since it allows the expression of f.i. peptides of the present invention in cells or individuals which are immunized with the live recombinant vaccinia virus.
- AMV Ankara Modified Virus
- insect expression transfer vectors derived from baculovirus Autographa californica nuclear polyhedrosis virus (AcNPV), which is a helper- independent viral expression vector.
- AcNPV Autographa californica nuclear polyhedrosis virus
- Expression vectors derived from this system usually use the strong viral polyhedrin gene promoter to drive the expression of heterologous genes.
- Different vectors as well as methods for the introduction of heterologous DNA into the desired site of baculovirus are available to the man skilled in the art for baculovirus expression.
- signals for posttranslational modification recognized by insect cells are known in the art.
- the present invention also relates to a host cell transformed with a recombinant vector as defined above.
- the present invention also relates to antibodies that are specifically raised against the peptides of the present invention, preferably against those peptides wherein the arginines are derivatized towards citrulline. These antibodies may be polyclonal or monoclonal.
- a host animal is immunized using the peptides of the present invention in a pharmaceutically acceptable carrier, wherein at least one of the arginines is derivatized towards citrulline.
- Pharmaceutically acceptable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition.
- Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers; and inactive virus particles. Such carriers are well known to those of ordinary skill in the art.
- Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to : aluminim hydroxide (alum), N-acetyl-muramyl-L-threonyl-D- isoglutamine (thr-MDP) as found in U.S. Patent No.
- N-acetyl- normuramyl-L-alanyl-D-isoglutamine (nor-MDP)
- N-acetylmuramyl-L-alanyl-D- isoglutaminyl-L-alanine-2-( 1 '-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)- ethylamine (MTP-PE)
- RIBI which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate, and cell wall skeleton (MPL + TDM + CWS) in a 2% squalene/Tween 80 emulsion.
- any of the 3 components MPL, TDM or CWS may also be used alone or combined 2 by 2. Additionally, adjuvants such as Stimulon (Cambridge Bioscience, Worcester, MA) or SAF-1 (Syntex) may be used. Further, Complete Freund's Adjuvant (CFA) and
- IFA Incomplete Freund's Adjuvant
- the immunogenic compositions typically will contain pharmaceutically acceptable vehicles, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, preservatives, and the like, may be included in such vehicles.
- the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared.
- the preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect.
- the proteins may also be incorporated into Immune Stimulating Complexes together with saponins, for example Quil A (ISCOMS).
- Immunogenic compositions used to raise antibodies comprise a 'sufficient amount' or 'an immunologically effective amount' of the peptides of the present invention, as well as any other of the above mentioned components, as needed.
- 'Immunologically effective amount' means that the administration of that amount to an individual, either in a single dose or as part of a series, is effective to provoke an immune response and to raise antibodies, as defined above. This amount varies depending upon the health and physical condition of the individual, the taxonomic group of the individual to be treated (e.g. nonhuman primate, primate, rabbit, etc.), the capacity of the individual's immune system to synthesize antibodies, the immunogenicity of the antigenic peptide, and its mode of administration, and other relevant factors.
- the amount will fall in a relatively broad range that can be determined through routine trials. Usually, the amount will vary from 0.01 to 1000 ⁇ g/dose, more particularly from 0.1 to 100 ⁇ g/dose.
- the immunogenic compositions are conventionally administered parenterally, typically by injection, for example, subcutaneously or intramuscularly. Additional formulations suitable for other methods of administration include oral formulations and suppositories. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- the vaccine may be administered in conjunction with other immunoregulatory agents.
- the host serum or plasma is collected following an appropriate time interval to provide a composition comprising antibodies reactive with the peptides of the present invention.
- the gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art.
- the antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs, for the treatment of infectious, chronic, or recurrent mononucleosis.
- Such antibodies may also be used to diagnose certain diseases, such as Burkitt's lymphoma, wherein Epstein-Barr virus has been implicated.
- the term 'immunogenic' refers to the ability of a substance to cause a humoral and/or cellular response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant.
- the antibodies of the claimed invention may also be monoclonals that are prepared with said antibody being specifically reactive with any of said peptides, and with said antibody being preferably a monoclonal antibody.
- the monoclonal antibodies of the invention can be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly from a mouse or rat, immunized against the claimed peptides of the present invention on the one hand, and of cells of a myeloma cell line on the other hand, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing the citrullinated forms of the peptides which has been initially used for the immunization of the animals.
- the antibodies involved in the invention can be labelled by an appropriate label of the enzymatic, fluorescent, or radioactive type.
- the monoclonal antibodies according to this preferred embodiment of the invention may be humanized versions of mouse monoclonal antibodies made by means of recombinant DNA technology, departing from parts of mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains.
- the monoclonal antibodies according to this preferred embodiment of the invention may be human monoclonal antibodies.
- These antibodies according to the present embodiment of the invention can also be derived from human peripheral blood lymphocytes of patients with rheumatoid arthritis.
- Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice (for recent review, see Duchosal et al. 1 992) or by screening vaccinated individuals for the presence of reactive B-cells by means of the antigens of the present invention.
- PBL peripheral blood lymphocytes
- SCID severe combined immune deficiency
- the present invention also relates to the anti-idiotype antibodies that are raised upon immunization with an antibody as defined above and that specifically react with said antibodies, thereby mimicking the peptides of the present invention.
- the present invention also relates to truncated versions or single chain versions of the antibodies and anti-idiotype antibodies as defined above, that have retained their original specificity for reacting with the antigens.
- the present invention also relates to proteins or peptides that mimic the antibodies as defined above such as microproteins as can be obtained by phage display or the highly variable domain of a recombinant antibody as obtained by screening upon repertoire cloning.
- the present invention also relates to a method for detecting antibodies that specifically react with the peptides or anti-idiotype antibodies of the present invention, present in a biological sample, comprising:
- the present invention also relates to a reverse method for detecting the peptides and/or the anti-idiotype antibodies of the present invention with antibodies present in a biological sample that specifically react with said peptides and/or anti- idiotype antibodies that mimic such peptides, comprising:
- the methods as defined above can be used in the diagnosis of rheumatoid arthritis.
- the present invention relates to the development of a diagnostic technique that allows differentiation between those autoimmune diseases in which the characteristic antibodies often crossreact with the same antigen, thus resulting in difficult and slow diagnosis.
- diagnostic technique can be obtained by the simultaneous use of several antigens and/or anti- idiotype antibodies of the present invention.
- the present invention also relates to a diagnostic kit for use in detecting the presence of said antibodies, said kit comprising at least one peptide or anti-idiotype antibody or microprotein as defined above, with said peptide or anti-idiotype antibody or microprotein being preferably bound to a solid support.
- the present invention also relates to a diagnostic kit for determining the type of autoimmune disease, said kit comprising at least one peptide or anti-idiotype antibody or microprotein as defined above, with said peptide or anti-idiotype antibody or microprotein being preferably bound to a solid support.
- the present invention also relates to a diagnostic kit as defined above, said kit comprising a range of said peptides and/or anti-idiotype antibodies or microprotein which are attached to specific locations on a solid substrate.
- the present invention also relates to a diagnostic kit as defined above, wherein said solid support is a membrane strip and said peptides and/or anti- idiotype antibodies or microproteins are coupled to the membrane in the form of parallel lines.
- the immunoassay methods according to the present invention may utilize for instance single or specific oligomeric antigens, dimeric antigens, as well as combinations of single or specific oligomeric antigens.
- the peptides of the present invention may be employed in virtually any assay format that employs a known antigen to detect antibodies that characterize a certain disease or infection.
- a common feature of all of these assays is that the antigenic peptide or anti-idiotype antibody or microprotein is contacted with the body component suspected of containing the antibodies under conditions that permit the antigen to bind to any such antibody present in the component. Such conditions will typically be physiologic temperature, pH and ionic strength using an excess of antigen.
- the incubation of the antigen with the specimen is followed by detection of immune complexes comprised of the antigen.
- Protocols may, for example, use solid supports, or immunoprecipitation.
- Most assays involve the use of labelled antibody or peptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules.
- Assays which amplify the signals from the immune complex are also known; examples of which are assays which utilize biotin and avidin or streptavidin, and enzyme-labelled and mediated immunoassays, such as EL1SA assays.
- the immunoassay may be, without limitation, in a heterogeneous or in a homogeneous format, and of a standard or competitive type.
- the peptide or anti-idiotype antibody or microprotein is typically bound to a solid matrix or support to facilitate separation of the sample from the peptide or anti-idiotype antibody or microprotein after incubation.
- solid supports examples include nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidene fluoride (known as ImmunolonTM), diazotized paper, nylon membranes, activated beads, and Protein A beads.
- nitrocellulose e.g., in membrane or microtiter well form
- polyvinyl chloride e.g., in sheets or microtiter wells
- polystyrene latex e.g., in beads or microtiter plates, polyvinylidene fluoride (known as ImmunolonTM)
- diazotized paper e.g., in beads or microtiter plates
- Dynatech ImmunolonTM 1 or ImmunolonTM 2 microtiter plates or 0.25 inch polystyrene beads (Precision Plastic Ball) can be used
- the test sample is incubated with the combination of antigens in solution.
- it may be under conditions that will precipitate any antigen-antibody or anti-idiotype antibody-antibody or microprotein-antibody complexes which are formed.
- Both standard and competitive formats for these assays are known in the art.
- the amount of rheumatoid arthritis antibodies in the antibody- antigen complexes is directly monitored. This may be accomplished by determining whether a second type of labelled anti-xenogenetic (e.g. anti-human) antibodies which recognize an epitope on the first type of rheumatoid arthritis-antibodies will bind due to complex formation.
- the amount of rheumatoid arthritis-antibodies in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labelled antibody (or other competing ligand) in the complex.
- the detection of rheumatoid arthritis-antibodies for diagnosis of rheumatoid arthritis is used as an illustration. Wherever the term " rheumatoid arthritis-antibodies" is used throughout the specification, this should not be considered as limitative.
- the other autoimmune diseases are diagnosed by detection of other antibodies, and mononucleosis is diagnosed by detection of anti-Epstein-Barr virus antibodies.
- Complexes formed comprising rheumatoid arthritis-antibody are detected by any of a number of known techniques, depending on the format.
- unlabelled rheumatoid arthritis-antibodies in the complex may be detected using a conjugate of anti-xenogenetic Ig complexed with a label (e.g. an enzyme label) .
- a label e.g. an enzyme label
- the reaction between the rheumatoid arthritis-antigens and the rheumatoid arthritis-antibody forms a network that precipitates from the solution or suspension and forms a visible layer or film of precipitate.
- PA particle agglutination
- the antigenic peptides of the present invention will typically be packaged in the form of a kit for use in these immunoassays.
- the kit will normally contain in separate containers the antigenic peptide or anti-idiotype antibody, control antibody formulations (positive and/or negative), labelled antibody when the assay format requires the same and signal generating reagents (e.g. enzyme substrate) if the label does not generate a signal directly.
- the antigenic peptide or anti-idiotype antibody may be already bound to a solid matrix or separate with reagents for binding it to the matrix. Instructions (e.g. written, tape, CD-ROM, etc.) for carrying out the assay usually will be included in the kit.
- the solid phase selected can include polymeric or glass beads, nitrocellulose, microparticles, microwells of a reaction tray, test tubes and magnetic beads.
- the signal generating compound can include an enzyme, a luminescent compound, a chromogen, a radioactive element and a chemiluminescent compound. Examples of enzymes include alkaline phosphatase, horseradish peroxidase and beta- galactosidase.
- enhancer compounds include biotin, anti-biotin and avidin.
- enhancer compounds binding members include biotin, anti- biotin and avidin.
- the test sample is subjected to conditions sufficient to block the effect of rheumatoid factor-like substances. These conditions comprise contacting the test sample with a quantity of for instance Rabbit Ig or anti-human IgG, preferably aggregated, to form a mixture, and incubating the mixture for a time and under conditions sufficient to form a reaction mixture product substantially free of rheumatoid factor-like substance.
- the present invention particularly relates to an immunoassay format in which several peptides of the invention are coupled to a membrane in the form of parallel lines.
- This assay format is particularly advantageous for allowing a discrimination between the separate autoimmune diseases.
- the present invention refers to a bioassay for identifying compounds which modulate the binding between an autoantigen and a rheumatoid arthritis specific autoantibody comprising: i) - contacting rheumatoid arthritis specific autoantibodies with any of the above mentioned peptides or intermediate filament proteins or a combination thereof.
- the present invention refers to a modulator for the interaction between an autoantigen and a rheumatoid arthritis specific autoantibody, and the method for producing said modulator, wherein said modulator is identified by the bioassay described above.
- compound as used herein has to be interpreted in a broad sense and can be proteins, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules, or antibodies which may be generated by the host itself upon vaccination.
- binding indicates that a peptide as described above is physically connected to, and interacts with antibodies. Binding of the peptide to the antibody can be demonstrated by any method or assay known in the art such as binding-, ELISA, and RIA-type of assays or competition assays (eg see Examples section and Current protocols in immunology).
- modulation or “modulate” as used herein refer to both upregulation (i.e., activation or stimulation (e.g., by agonizing or potentiating)) and downregulation (i.e. inhibition or suppression (e.g. by antagonizing, decreasing or inhibiting) of the binding between a peptide and an anti-HCV antibody.
- modulator refer to the ability of a compound as described above to modulate as described above.
- peptidomimetics refers to molecules which can be manufactured and which mimic those residues of peptides which modulate the interaction of the antibody with the peptide as described above.
- non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al. in Peptides: Chemistry and Biology, G. R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1 988), azepine (e.g., see Huffman et al. in Peptides: Chemistry and Biology, G. R.
- Fig 1 HPLC profile of tryptic digests of human natural acidic (a) and neutral (b) filaggrin.
- Peptides were separated by reversed-phase HPLC on a C-4 Vydac column (2.1 x 250 mm, Hesperia, CA) using a 140B Solvent Delivery System (ABI, Foster City, CA) and eluted with a 8-70% linear gradient of 70% acetonitrile in 0.1 % trifluoroacetic acid (TFA). Detection occured at 21 4 nm with a 1 000S diode array detector.
- TFA trifluoroacetic acid
- Fig3 Reactivity of 26 human RA sera with synthetic peptides on LIA.
- IGP1 1 54 consisted of an irrelevant synthetic peptide.
- Fig4 Inhibition ELISA using natural filaggrin as inhibitory agent. Plates were coated with purified human natural filaggrin at 1 ⁇ g/ml. Sera were diluted 1 /50 and added to the plate with or without preincubation with natural filaggrin at 1 or 10 ⁇ g/ml. OD values were measured at 450 nm.
- Fig5 Inhibition ELISA using synthetic citrulline-containing filaggrin peptides as inhibitory agents.
- Plates were coated with purified human natural filaggrin at 4 ⁇ g/ml.
- Sera were diluted 1 /50 and added to the plate with or without preincubation with the individual peptides (IGP1 1 55, 1 1 56, 1 1 57, 1 1 58) or a mixture of the four peptides (mix), each at 1 00 ⁇ g/ml.
- OD values were measured at 450 nm.
- Fig 7 2-D immunoblots of placental extracts.
- Natural filaggrin was purified from human skin obtained freshly after abdominoplasty according to the protocol of Simon et al. (1 993) .
- the epidermis was separated from the dermis by incubating the skin pieces at 56° C in PBS containing 5 mM EDTA. The material was stored dry at -20°C untill use.
- the epidermis was cut into small pieces which were homogenized in 40 mM Tris-HCI, pH 7.4, 1 50 mM NaCI, 5 mM EDTA, 0.5% NP-40, 0.1 % sodium azide, 0.1 mM PMSF (0.2 ml/cm 2 ) and stirred overnight at 4°C.
- the homogenate was centrifuged at 1 5,000 x g for 1 5 min and the extracted proteins in the supernatant were precipitated overnight at -20 °C by adding 5 volumes of absolute ethanol. After centrifugation for 1 5 min at 1 0,000 x g, the protein pellet was vacuum-dried and subsequently resuspended in water. This partially purified protein preparation is refered to filaggrin used in the present study. The amount of protein was determined by the Bradford protein assay as modified by Peterson (1 983) using BSA standard curves.
- the crude filaggrin preparation was submitted to 10% Tricine SDS-PAGE using the
- Bio-Rad mini-gel apparatus Two ⁇ g protein/cm was loaded in a large slot and electrophoresed under standard conditions. The gel was subsequently electroblotted onto nitrocellulose membrane in 10% methanol, 10 mM CAPS, pH 1 1 .0 during 40 min. The blot was blocked in PBS, 0.05% Tween20, 1 % gelatin and cut into 3 mm strips, which were probed with human sera overnight at a 1 /1 00 dilution in PBS, 0.05% Tween20, 0.1 % gelatin. As a secondary antibody the anti-human IgG-AP conjugate (Sigma, St Louis, Ml) was added at a 1 /1000 dilution; visualization occured with the NBT/BCIP chromogenic substrate.
- the filaggrin material was separated by 2-D electrophoresis using Immobiline DryeStrips pH 3-1 0 (Pharmacia Biotech, Uppsala, Sweden) in the first dimension and 1 0% Tricine SDS-PAGE in the second dimension using standard procedures.
- Preparative gels were loaded with 300 ⁇ g protein and stained with Coomassie R- 250.
- the large comma-shaped filaggrin spot was identified by immunoreaction with the antifilaggrin mAb (BTI, Stoughton, MA) .
- the pi of this heterogeneous protein ranged from 6.7-8.5 (7.1 -8.5 on gel), while molecular weight forms of 35-68 kDa were detected, with the more acidic isoforms representing the highest masses.
- the large filaggrin spot was cut out of the gel and separated into three parts: i) acidic fraction with pi 7.1 -7.5; ii) neutral fraction with pi 7.5-8.1 ; iii) basic fraction with pi 8.1 -8.5.
- Each fraction was electro-eluted by the method of Hunkapiller et al. ( 1 983) using 50 mM (NH 4 )HC0 3 , 0.1 % SDS as elution buffer.
- Coomassie stain and SDS were removed from the eluted proteins by ion pair extraction as described by K ⁇ nigsberg and Henderson (1 983). Vacuum-dried protein pellets were redissolved in the appropriate buffer for further analysis.
- Peptides were separated by reversed-phase HPLC on a C-4 Vydac column (2.1 x 250 mm, Hesperia, CA) using a 1 40B Solvent Delivery System (ABI, Foster City, CA) and eluted with a 8-70% linear gradient of 70% acetonitrile in 0.1 % trifluoroacetic acid (TFA). Detection occured at 21 4 nm with a 1 000S diode array detector and peptides were manually recovered.
- TFA trifluoroacetic acid
- APF serum pool also scored positive with both T34 and T38, while IG35247 was only reactive with T4.
- the APF negative control serum was clearly unreactive with the peptide fractions.
- T38 T39: Same peptides as in fraction T35
- ⁇ represents the amino acid citrulline, which was found at a specific retention time different from that of arginine. Further proove for the presence of citrulline was i) the fact that the sequence was not cleaved at that specific position, which would be expected if arginine was present and ii) that no arginine residue was sequenced.
- T45 and T81 There was one fraction (T48) that showed aspecific reactivity with all sera including the negative control serum.
- T48 There was one fraction (T48) that showed aspecific reactivity with all sera including the negative control serum.
- T32, T36, T37, T48 and T65 yielded no reliable amino acid sequencing signals.
- the fifth peptide was clearly derived from the second peptide, most probably due to the fact that in the neutral filaggrin two forms with and without citrulline- modification do exist. These results indicate that the same four peptides were retrieved as identified in the acidic T35 fraction.
- T28, T31 , T34 yielded no sequencable signals.
- IGP1 1 56 IGP1180
- IGP1158 IGP1182 HSTSQEGQDTIHGHRGS HSTSQEGQDTIHGHRGS
- Streptavidin-complexed peptides were applied directly on a nylon membrane with a plastic backing. Blocked strips were incubated overnight with human sera diluted 1 /1 00 in 1 ml PBS, 0.5% caseine, 0.1 % Triton X705, 1 0 mM MgCI 2 .6H 2 O. After washing with PBS, 0.05% Tween20, goat anti-human IgG-AP conjugated (Promega) diluted in PBS, 0. 1 % caseine, 0.2% Triton X705 was added for 1 h30.
- Strips were developed in 1 00 mM NaCI, 1 00 mM Tris-HCI, pH 9.8, 50 mM MgCI 2 .6H 2 O substrate buffer containing the chromogenic substrate NBT/ BCIP. Reaction was stopped after 30 min by addition of 0.2 N H 2 SO 4 .
- IGP1 1 55, IGP1 1 56, IGP1 1 57, and IGP1 1 58 were not retrieved when tested with the non-modified counterparts IGP1 1 79, IGP1 1 80, IGP1 1 81 , and IGP1 1 82 (Fig. 3). Only for 2 sera, a weak colouring of all non-modified peptides was obtained, which could be regarded as aspecific background staining related to the particular sera. These results indicate that the presence of citrulline is indispensable for immunoreactivity and that this unusual amino acid constitutes an important epitope for antifilaggrin antibodies.
- Electro-eluted human natural filaggrin was coated in Maxisorp polystyrene plates at a concentration of 1 or 4 ⁇ g/ml in 50 mM carbonate buffer, pH 9.6 overnight at 4°C.
- Sera were diluted 1 /50 in PBS, and preincubated with either the appropriate peptides at 1 00 ⁇ g/ml, with isolated natural filaggrin at 1 or 1 0 ⁇ g/ml (positive control) or with PBS (negative control) for 2 hours.
- the plates were blocked 1 hour with PBS, 0.1 % case ⁇ ne at 37°C and subsequently incubated with the sera. During 2 hours at 37 ° C.
- PCR primers were designed as follows:
- the PCR sense primer was chosen to overlap the filaggrin linker sequence and was designed to introduce a functional initiation codon (Kozak environment) upstream of the linker sequence (Phe Leu Tyr Gin Val Ser Thr) .
- the linker sequence was included in the amplified filaggrin repeat, because it is possibly involved in the correct targetting of the processed protein.
- An EcoRI restriction site was introduced for subcloning of the PCR fragment.
- the antisense PCR primer is the antisense PCR primer
- the antisense primer is located just upstream from the next filaggrin linker sequence and introduces a translation stop codon TAG.
- the amplified filaggrin sequence consists therefore of the filaggrin linker followed by an integral filaggrin repeat and three additional amino acids (Pro/Gly/His) resulting from the cloning strategy.
- the PCR amplified fragments were cloned in a pBLSK
- the four individual clones characterized by sequencing were named HB2641 , HB2642, HB2648 and HB2650 (Fig 6) .
- the cDNA inserts were recloned as EcoRV/Ecl 1 3611 fragments ( 1 030 bp) in the E. coli expression vector pIGRHISA opened with Hsil blunted.
- the filaggrin proteins were expressed as recombinant filaggrin-His ⁇ fusion proteins in three different E. Coli strains, resulting in high Coomassie stainable expression levels.
- the His6 tail of the fusion protein allows easy purification of the protein using metal-affinity chromatography.
- Example 5 Vimentin as marker for diagnosis of rheumatoid arthritis
- Placental tissue stored at -70°C was homogenized in 50 mM Tris-HCI, pH 7.4, 1 20 mM NaCI, 1 .5 mM DTT, 0.02% NaN 3 , 1 mM PMSF, and 5 ⁇ g/ml of chymostatin, leupeptin, antipain, pepstatin. After clarification, the homogenate was subjected to DE52 ion exchange chromatography; the 200, 250 and 300 mM salt elution fractions were further analyzed by 1 - and 2-D gelelectrophoresis.
- Proteins present in the different chromatographic fractions were separated by 2- D gel electrophoresis. Samples were resolved in rehydration buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% Triton X-1 00, 1 % Pharmalytes 3-10, 1 0 mM DTT, 0.01 % Orange G. Fifty-500 ⁇ g of protein was applied onto IPG4-7 iso-electrofocusing strips (Pharmacia) by the in-gel rehydration method of Rabilloud et al. (1 997). First dimension strips were loaded on 1 0% Laemmli gels or SDS Gradient 1 2-1 4 ExcelGels (Pharmacia) for second dimension running according to standard procedures.
- Coomassie-stained protein spots were cut out from 2-D gels, washed with water and 50% acetonitrile/ 1 % TFA and incubated with 0.08 ⁇ g trypsine in 1 0 ⁇ l 25 mM NH 4 HC0 3 / 1 0% acetonitrile, pH 8.0 during 20 hours at 37 ° C. Peptides were extracted with 60% acetonitrile/ 0.1 % TFA, vacuum-dried and redissolved in 1 0 ⁇ l 30% MeOH/ 1 % formic acid. Approximately 5% of the digest mixture was subjected to DE-MALDI-RETOF-MS analysis on a Voyager-DE STR (Perseptive Biosystems, Framingham, MA).
- Calreticulin was found as an abundant spot of 56-61 kDa, pi 4.3, while PDI was observed at 58-64 kDa with a pi of 4.6-4.8, hence both corresponding to the expected theoretical 2-D positions. The latter spot was further identified as being PDI by tandem MS analysis.
- the anti-vimentin mAb showed strong reactivity as shown in Fig 7b with numerous proteins between 40 and 61 kDa. This pattern proved highly reproducable between different batches of purified material, even when derived from different persons and tested at different points in time. Upon superimposing the blots probed with RA sera on the anti-vimentin blot, it became clear that the RA-specific reactivity colocalized with the high MW form of vimentin.
- the spots of intrest were further identified by MALDI-TOF and tandem mass spectrometry.
- peptides from human vimentin, cytokeratin 1 and cytokeratin 9 were retrieved in addition to other non- identified peptides. These proteins all belong to the same family of intermediate filament proteins.
- citrullinated forms of vimentin and cytokeratins are already described to occur in vivo (Senshu et al., 1 992; Senshu et al., 1 995; Senshu et al., 1 996) , it is likely that they constitute targets for autoantibodies present in rheumatoid arthritis sera.
- Citrullinated proteins have been shown to cause a mobility shift on SDS-PAGE towards higher MW regions in comparison with the non-citrullinated forms (Senshu et al., 1 995; Tarcsa et al., 1 996), which could explain the selective immunoreactivity of the human sera to the highest MW forms of vimentin.
- Specific intermediate filament protein forms could hence be used as marker for diagnosing rheumatological disorders.
- the Sa system a novel antigen-antibody system specific for rheumatoid arthritis.
- Vincent C Serre G., Lapeyre F., Fournie B., Ayrolles C, Fournie A., Soleilhavoup J.-P. (1989) High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies'. 1 989. Ann. Rheum. Dis., 48: 71 2-722 Vincent C, Serre G., Basiie J.-P., Lestra H.C., Girbal E., Sebbag M.,
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL98344534A PL344534A1 (en) | 1997-11-28 | 1998-11-30 | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
CA002309534A CA2309534A1 (en) | 1997-11-28 | 1998-11-30 | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
JP2000523235A JP2002512939A (en) | 1997-11-28 | 1998-11-30 | Citrulline-containing synthetic peptide recognized by serum of rheumatoid arthritis as a tool for diagnosis and treatment |
EP98965715A EP1034186A2 (en) | 1997-11-28 | 1998-11-30 | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
AU21558/99A AU2155899A (en) | 1997-11-28 | 1998-11-30 | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97870195 | 1997-11-28 | ||
EP97870195.1 | 1997-11-28 | ||
EP98870078.7 | 1998-04-09 | ||
EP98870078A EP0949270A1 (en) | 1998-04-09 | 1998-04-09 | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999028344A2 true WO1999028344A2 (en) | 1999-06-10 |
WO1999028344A3 WO1999028344A3 (en) | 1999-08-12 |
Family
ID=26148315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/007714 WO1999028344A2 (en) | 1997-11-28 | 1998-11-30 | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1034186A2 (en) |
JP (1) | JP2002512939A (en) |
AU (1) | AU2155899A (en) |
CA (1) | CA2309534A1 (en) |
CZ (1) | CZ20001963A3 (en) |
HU (1) | HUP0004338A2 (en) |
PL (1) | PL344534A1 (en) |
WO (1) | WO1999028344A2 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001046222A2 (en) * | 1999-12-21 | 2001-06-28 | Innogenetics N.V. | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
FR2826124A1 (en) * | 2001-06-13 | 2002-12-20 | Bio Merieux | Detecting auto-antibodies specific for rheumatoid polyarthritis, useful for diagnosis, based on their differential reaction with native and citrullinated filaggrin |
EP1041997B1 (en) * | 1997-12-30 | 2003-04-16 | Universite Paul Sabatier (Toulouse Iii) | Use of citrulline peptides derived from filaggrin for treating autoimmune diseases |
WO2003050542A2 (en) * | 2001-12-11 | 2003-06-19 | Stichting Voor De Technische Wetenschappen | Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assaykit |
WO2005010531A1 (en) * | 2003-07-29 | 2005-02-03 | Kurt Herkner | Biochemical diagnostic means for screening for rheumatoid arthritis |
WO2005012911A1 (en) * | 2003-07-29 | 2005-02-10 | Solvay Pharmaceuticals Gmbh | Analytical method for pancreatin and comparable compositions |
WO2007068946A2 (en) * | 2005-12-15 | 2007-06-21 | University Court Of The University Of Dundee | Identification of loss-of-function mutations in filaggrin causing ichthyosis vulgaris and predisposing to other diseases |
EP1980855A1 (en) | 2004-02-27 | 2008-10-15 | Roche Diagnostics GmbH | Method of assessing rheumatoid arthritis by measuring anti-CCP and serum amyloid A |
WO2009070875A1 (en) * | 2007-12-03 | 2009-06-11 | Sqi Diagnostics Systems Inc. | Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies |
WO2009147201A2 (en) * | 2008-06-04 | 2009-12-10 | Modiquest B.V. | Anti-inflammatory agents |
US7846674B2 (en) | 2003-12-23 | 2010-12-07 | Roche Diagnostics Operations, Inc. | Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6 |
WO2010117694A3 (en) * | 2009-03-30 | 2011-01-20 | Prometheus Laboratories Inc. | Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis |
EP2325195A1 (en) | 2009-11-23 | 2011-05-25 | Toscana Biomarkers S.r.l. | Viral citrullinated peptides and uses thereof |
EP2336769A1 (en) | 2009-12-18 | 2011-06-22 | F. Hoffmann-La Roche AG | Trigger assay for differentiating between rheumatic and non-rheumatic disorders |
US8058013B2 (en) | 2006-09-29 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Assessing risk of disease progression in rheumatoid arthritis patients |
EP2402368A1 (en) | 2010-07-02 | 2012-01-04 | Toscana Biomarkers S.r.l. | Histone citrullinated peptides and uses thereof |
EP2527841A1 (en) | 2011-05-25 | 2012-11-28 | Toscana Biomarkers S.r.l. | Methods for the diagnosis of rheumatoid arthritis |
US8351372B2 (en) | 1997-11-03 | 2013-01-08 | Qualcomm Incorporated | Method and apparatus for high rate packet data transmission |
US20140170773A1 (en) * | 2011-08-12 | 2014-06-19 | Hiroshima University | Method for detecting asbestos |
JP2014517296A (en) * | 2011-05-27 | 2014-07-17 | ノルディック・ビオサイエンス・エー/エス | Detection of diagnostic peptides |
WO2015010791A2 (en) | 2013-07-24 | 2015-01-29 | Klareskog, Lars | Novel antibodies for the diagnosis and treatment of rheumatoid arthritis |
US9018244B2 (en) | 2011-12-16 | 2015-04-28 | Olema Pharmaceuticals, Inc. | Benzopyran compounds, compositions and uses thereof |
KR20150143025A (en) * | 2014-06-13 | 2015-12-23 | 한국생명공학연구원 | probes, kits and methods for detecting mutation of filaggrin gene |
US20160024183A1 (en) * | 2013-03-12 | 2016-01-28 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Synthetic peptides for the treatment of autoimmune diseases |
EP3056904A1 (en) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-MCM3 |
EP3056903A1 (en) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-Casp8 |
WO2016128348A1 (en) | 2015-02-13 | 2016-08-18 | F. Hoffmann-La Roche Ag | Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
CN111007262A (en) * | 2019-12-25 | 2020-04-14 | 漳州卫生职业学院 | Kit for auxiliary diagnosis of RA and detection method |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
FR2900657B1 (en) * | 2006-05-03 | 2009-04-17 | Univ Toulouse | IDENTIFICATION OF MACROPHAGE ACTIVATION MODULATORS, USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019649A1 (en) * | 1991-04-26 | 1992-11-12 | Clonatec | Antigens recognized by antibodies of rhumatoid polyarthritis, and preparation and use thereof |
US5660994A (en) * | 1986-11-10 | 1997-08-26 | Progen Biotechnik Gmbh | Method of detecting tissue-specific, insoluble cytoskeletal proteins |
WO1998008946A1 (en) * | 1996-08-30 | 1998-03-05 | Biomerieux | Antigens derived from filaggrin and their use for diagnosing rheumatoid polyarthritis |
WO1998022503A2 (en) * | 1996-11-15 | 1998-05-28 | Stichting Scheikundig Onderzoek Nederland | Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto-immune antibodies |
-
1998
- 1998-11-30 JP JP2000523235A patent/JP2002512939A/en active Pending
- 1998-11-30 PL PL98344534A patent/PL344534A1/en unknown
- 1998-11-30 EP EP98965715A patent/EP1034186A2/en not_active Withdrawn
- 1998-11-30 AU AU21558/99A patent/AU2155899A/en not_active Withdrawn
- 1998-11-30 CA CA002309534A patent/CA2309534A1/en not_active Abandoned
- 1998-11-30 WO PCT/EP1998/007714 patent/WO1999028344A2/en not_active Application Discontinuation
- 1998-11-30 HU HU0004338A patent/HUP0004338A2/en unknown
- 1998-11-30 CZ CZ20001963A patent/CZ20001963A3/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5660994A (en) * | 1986-11-10 | 1997-08-26 | Progen Biotechnik Gmbh | Method of detecting tissue-specific, insoluble cytoskeletal proteins |
WO1992019649A1 (en) * | 1991-04-26 | 1992-11-12 | Clonatec | Antigens recognized by antibodies of rhumatoid polyarthritis, and preparation and use thereof |
WO1998008946A1 (en) * | 1996-08-30 | 1998-03-05 | Biomerieux | Antigens derived from filaggrin and their use for diagnosing rheumatoid polyarthritis |
WO1998022503A2 (en) * | 1996-11-15 | 1998-05-28 | Stichting Scheikundig Onderzoek Nederland | Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto-immune antibodies |
Non-Patent Citations (5)
Title |
---|
E. TARCSA ET AL.: "Protein unfolding by peptidylarginine deiminase" J. BIOLOGICAL CHEMISTRY, vol. 271, no. 48, November 1996, pages 30709-30716, XP002105187 * |
G.A. SCHELLEKENS ET AL.: "CITRULLINE IS AN ESSENTIAL CONSTITUENT OF ANTIGENIC DETERMINANTS RECOGNISED BY RHEUMATOID ARTHRITIS-SPECIFIC AUTOANTIBODIES" J. CLIN. INVEST., vol. 101, no. 1, January 1998, pages 273-281, XP002105185 * |
SCHELLEKENS G A ET AL: "THE MODIFIED ARGININE RESIDUE CITRULLINE IS THE MAJOR CONSTITUENT OF EPITOPES RECOGNIZED BY AUTOANTIBODIES IN SERA FROM RHEUMATOID ARTHRITIS PATIENTS" ARTHRITIS AND RHEUMATISM, vol. 40, no. 9, SUPPL. 08, 8 November 1997, page S276 XP002067877 * |
SIMON M ET AL: "THE CYTOKERATIN FILAMENT-AGGREGATING PROTEIN FILAGGRIN IS THE TARGET OF THE SO-CALLED " ANTIKERATIN ANTIBODIES," AUTOANTIBODIES SPECIFIC FOR RHEUMATOID ARTHRITIS" JOURNAL OF CLINICAL INVESTIGATION, vol. 92, no. 3, 1 September 1993, pages 1387-1393, XP002038026 * |
T.SENSHU ET AL: "Preferential deimination of keratin K1 and Filaggrin during the terminal differentiation of human epidermis" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 225, 1996, pages 712-719, XP002105186 ORLANDO, FL US * |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8351372B2 (en) | 1997-11-03 | 2013-01-08 | Qualcomm Incorporated | Method and apparatus for high rate packet data transmission |
EP1041997B1 (en) * | 1997-12-30 | 2003-04-16 | Universite Paul Sabatier (Toulouse Iii) | Use of citrulline peptides derived from filaggrin for treating autoimmune diseases |
WO2001046222A2 (en) * | 1999-12-21 | 2001-06-28 | Innogenetics N.V. | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
WO2001046222A3 (en) * | 1999-12-21 | 2002-01-17 | Innogenetics Nv | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
FR2826124A1 (en) * | 2001-06-13 | 2002-12-20 | Bio Merieux | Detecting auto-antibodies specific for rheumatoid polyarthritis, useful for diagnosis, based on their differential reaction with native and citrullinated filaggrin |
US8241856B2 (en) | 2001-06-13 | 2012-08-14 | Biomerieux | Method for detecting rheumatoid arthritis-specific autoantibodies |
US8759114B2 (en) * | 2001-12-11 | 2014-06-24 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
WO2003050542A3 (en) * | 2001-12-11 | 2003-12-11 | Stichting Tech Wetenschapp | Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assaykit |
WO2003050542A2 (en) * | 2001-12-11 | 2003-06-19 | Stichting Voor De Technische Wetenschappen | Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assaykit |
NL1019540C2 (en) * | 2001-12-11 | 2003-07-01 | Stichting Tech Wetenschapp | Method for detecting autoantibodies from patients suffering from rheumatoid arthritis, peptide and assay kit. |
AU2002354397B2 (en) * | 2001-12-11 | 2006-07-20 | Stichting Voor De Technische Wetenschappen | Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
EP1693673A2 (en) * | 2001-12-11 | 2006-08-23 | Stichting Voor De Technische Wetenschappen | Detection of auto-antibodies from patients suffering from rheumatoid arthritis |
EP1693673A3 (en) * | 2001-12-11 | 2006-12-06 | Stichting Voor De Technische Wetenschappen | Detection of auto-antibodies from patients suffering from rheumatoid arthritis |
US10119966B2 (en) | 2001-12-11 | 2018-11-06 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and assay kit |
CN105699648B (en) * | 2001-12-11 | 2017-10-20 | 技术科学基金会 | Method, peptide and the detection kit of autoantibody are detected from the patient with rheumatoid arthritis |
US9689871B2 (en) | 2001-12-11 | 2017-06-27 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
CN100424509C (en) * | 2001-12-11 | 2008-10-08 | 技术科学基金会 | Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
US8481332B2 (en) | 2001-12-11 | 2013-07-09 | Stichting Voor de Technische Wetenshappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
US7888133B2 (en) | 2001-12-11 | 2011-02-15 | Stichting Voor De Technische Wetenschappen | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
CN105699648A (en) * | 2001-12-11 | 2016-06-22 | 技术科学基金会 | Method of detecting auto-antibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
EP2071335A3 (en) * | 2001-12-11 | 2009-09-02 | Stichting Voor De Technische Wetenschappen | Detection of auto-antibodies from patients suffering from rheumatoid arthritis |
AU2010200648B2 (en) * | 2001-12-11 | 2012-07-12 | Stichting Voor De Technische Wetenschappen | Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assay kit |
CN103524603A (en) * | 2001-12-11 | 2014-01-22 | 技术科学基金会 | A method of detecting autoantibodies from patients suffering from rheumatoid arthritis, a peptide and an assaykit |
CN101408546B (en) * | 2001-12-11 | 2013-10-30 | 技术科学基金会 | Method of detecting autoantibodies from patients suffering from rheumatoid arthritis, peptide and assaykit |
US7479378B2 (en) | 2003-07-29 | 2009-01-20 | Solvay Pharmaceuticals Gmbh | Method of analyzing enzyme compositions with lipolytic, proteolytic and amylolytic activity |
WO2005010531A1 (en) * | 2003-07-29 | 2005-02-03 | Kurt Herkner | Biochemical diagnostic means for screening for rheumatoid arthritis |
AT413768B (en) * | 2003-07-29 | 2006-05-15 | Herkner Kurt Dipl Ing Dr Techn | BIOCHEMICAL DIAGNOSTIC TO DETECT RHEUMATOID ARTHRITIS |
WO2005012911A1 (en) * | 2003-07-29 | 2005-02-10 | Solvay Pharmaceuticals Gmbh | Analytical method for pancreatin and comparable compositions |
US7846674B2 (en) | 2003-12-23 | 2010-12-07 | Roche Diagnostics Operations, Inc. | Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6 |
EP1980855A1 (en) | 2004-02-27 | 2008-10-15 | Roche Diagnostics GmbH | Method of assessing rheumatoid arthritis by measuring anti-CCP and serum amyloid A |
US7981693B2 (en) | 2004-02-27 | 2011-07-19 | Roche Diagnostics Operations, Inc. | Combined measurement of anti-CCP and serum amyloid A to assess rheumatoid arthritis |
US8062907B2 (en) | 2004-02-27 | 2011-11-22 | Roche Diagnostics Operations, Inc. | Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A |
US10704037B2 (en) | 2005-07-29 | 2020-07-07 | Abbott Products Gmbh | Processes for the manufacture and use of pancreatin |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
WO2007068946A2 (en) * | 2005-12-15 | 2007-06-21 | University Court Of The University Of Dundee | Identification of loss-of-function mutations in filaggrin causing ichthyosis vulgaris and predisposing to other diseases |
WO2007068946A3 (en) * | 2005-12-15 | 2007-12-21 | Univ Dundee | Identification of loss-of-function mutations in filaggrin causing ichthyosis vulgaris and predisposing to other diseases |
GB2447202A (en) * | 2005-12-15 | 2008-09-03 | Univ Dundee | Identification of loss-of-function mutations in filaggrin causing ichthyosis vulgaris and predisposing to other diseases |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
US8058013B2 (en) | 2006-09-29 | 2011-11-15 | Roche Diagnostics Operations, Inc. | Assessing risk of disease progression in rheumatoid arthritis patients |
JP2011505390A (en) * | 2007-12-03 | 2011-02-24 | エスキューアイ・ダイアグノスティクス・システムズ・インコーポレイテッド | Synthetic immunoreactive peptides with rheumatoid arthritis autoantibodies |
CN101918432B (en) * | 2007-12-03 | 2015-02-25 | Sqi诊断系统公司 | Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies |
US8318440B2 (en) | 2007-12-03 | 2012-11-27 | Sqi Diagnostics Systems Inc. | Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies |
AU2008331381B2 (en) * | 2007-12-03 | 2013-08-22 | Sqi Diagnostics Systems Inc. | Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies |
WO2009070875A1 (en) * | 2007-12-03 | 2009-06-11 | Sqi Diagnostics Systems Inc. | Synthetic peptides immuno-reactive with rheumatoid arthritis auto-antibodies |
KR101752499B1 (en) | 2008-06-04 | 2017-06-29 | 모디퀘스트 비.브이. | Anti-inflammatory agents |
WO2009147201A3 (en) * | 2008-06-04 | 2010-01-28 | Modiquest B.V. | Anti-inflammatory agents |
US9718877B2 (en) | 2008-06-04 | 2017-08-01 | Modiquest B.V. | Anti-inflammatory agents |
WO2009147201A2 (en) * | 2008-06-04 | 2009-12-10 | Modiquest B.V. | Anti-inflammatory agents |
EA023302B9 (en) * | 2008-06-04 | 2016-10-31 | Модиквест Б.В. | Method for preventing or treating arthritis and use of an antibody specifically reactive with a citrullinated epitope in this method |
US10703822B2 (en) | 2008-06-04 | 2020-07-07 | Modiquest B.V. | Anti-inflammatory agents |
EA023302B1 (en) * | 2008-06-04 | 2016-05-31 | Модиквест Б.В. | Method for preventing or treating arthritis and use of an antibody specifically reactive with a citrullinated epitope in this method |
WO2010117694A3 (en) * | 2009-03-30 | 2011-01-20 | Prometheus Laboratories Inc. | Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis |
US8519096B2 (en) | 2009-03-30 | 2013-08-27 | Nestec S.A. | Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis |
EP3070097A3 (en) * | 2009-03-30 | 2016-11-23 | Nestec S.A. | Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis |
EP2325195A1 (en) | 2009-11-23 | 2011-05-25 | Toscana Biomarkers S.r.l. | Viral citrullinated peptides and uses thereof |
WO2011061720A2 (en) | 2009-11-23 | 2011-05-26 | Toscana Biomarkers S.R.L. | Viral citrullinated peptides and uses thereof |
EP2336769A1 (en) | 2009-12-18 | 2011-06-22 | F. Hoffmann-La Roche AG | Trigger assay for differentiating between rheumatic and non-rheumatic disorders |
EP2402368A1 (en) | 2010-07-02 | 2012-01-04 | Toscana Biomarkers S.r.l. | Histone citrullinated peptides and uses thereof |
WO2012001103A1 (en) | 2010-07-02 | 2012-01-05 | Toscana Biomarkers S.R.L. | Histone citrullinated peptides and uses thereof |
WO2012160127A1 (en) | 2011-05-25 | 2012-11-29 | Toscana Biomarkers S.R.L. | Method for the diagnosis of rheumatoid arthritis |
EP2527841A1 (en) | 2011-05-25 | 2012-11-28 | Toscana Biomarkers S.r.l. | Methods for the diagnosis of rheumatoid arthritis |
JP2014517296A (en) * | 2011-05-27 | 2014-07-17 | ノルディック・ビオサイエンス・エー/エス | Detection of diagnostic peptides |
US20140170773A1 (en) * | 2011-08-12 | 2014-06-19 | Hiroshima University | Method for detecting asbestos |
US9322822B2 (en) * | 2011-08-12 | 2016-04-26 | Hiroshima University | Method for detecting asbestos |
US9018244B2 (en) | 2011-12-16 | 2015-04-28 | Olema Pharmaceuticals, Inc. | Benzopyran compounds, compositions and uses thereof |
US20160024183A1 (en) * | 2013-03-12 | 2016-01-28 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Synthetic peptides for the treatment of autoimmune diseases |
US9975944B2 (en) * | 2013-03-12 | 2018-05-22 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Synthetic peptides for the treatment of autoimmune diseases |
WO2015010791A2 (en) | 2013-07-24 | 2015-01-29 | Klareskog, Lars | Novel antibodies for the diagnosis and treatment of rheumatoid arthritis |
KR20150143025A (en) * | 2014-06-13 | 2015-12-23 | 한국생명공학연구원 | probes, kits and methods for detecting mutation of filaggrin gene |
KR101634958B1 (en) | 2014-06-13 | 2016-06-30 | 한국생명공학연구원 | probes, kits and methods for detecting mutation of filaggrin gene |
US10094826B2 (en) | 2015-02-13 | 2018-10-09 | Roche Diagnostics Operations, Inc. | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD |
WO2016128348A1 (en) | 2015-02-13 | 2016-08-18 | F. Hoffmann-La Roche Ag | Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd |
EP3056903A1 (en) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-Casp8 |
EP3056904A1 (en) | 2015-02-13 | 2016-08-17 | F. Hoffmann-La Roche AG | Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-MCM3 |
CN111007262A (en) * | 2019-12-25 | 2020-04-14 | 漳州卫生职业学院 | Kit for auxiliary diagnosis of RA and detection method |
Also Published As
Publication number | Publication date |
---|---|
AU2155899A (en) | 1999-06-16 |
CZ20001963A3 (en) | 2002-04-17 |
WO1999028344A3 (en) | 1999-08-12 |
JP2002512939A (en) | 2002-05-08 |
HUP0004338A2 (en) | 2001-02-28 |
EP1034186A2 (en) | 2000-09-13 |
CA2309534A1 (en) | 1999-06-10 |
PL344534A1 (en) | 2001-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1034186A2 (en) | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment | |
EP0683234B2 (en) | Antibody against beta-amyloid or their derivative and use thereof | |
US5955317A (en) | Antibodies to β-amyloids or their derivatives and use thereof | |
US20020143143A1 (en) | Peptides designed for the diagnosis and treatment of rheumatoid arthritis | |
PT941244E (en) | Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide and a method of detecting auto-immune antibodies | |
JP4374316B2 (en) | Antibody to β-amyloid or a derivative thereof and use thereof | |
Tuaillon et al. | A lipoyl synthetic octadecapeptide of dihydrolipoamide acetyltransferase specifically recognized by anti-M2 autoantibodies in primary biliary cirrhosis. | |
AU751784B2 (en) | Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus | |
US20070161545A1 (en) | Triple polypeptide complexes | |
US5436320A (en) | Antibody reagents that identify the carboxy-terminal peptide of the GTP-binding protein Go | |
Levy et al. | Mapping B cell epitopes in Goodpasture's disease. | |
US5407833A (en) | Peptides of the SM-D antigen and their use for diagnosis of systemic lupus erythematosus | |
EP0949270A1 (en) | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment | |
US20060211056A1 (en) | Leishmania antigens suitable for a diagnostic kit of Leishmania | |
US7094576B2 (en) | Methods and compositions for detecting larval Taenia solium with a cloned diagnostic antigen | |
US7491515B2 (en) | Recombinant polypeptides for diagnosing infection with Trypanosoma cruzi | |
JP2002107363A (en) | Method for assaying human aging marker and stress marker | |
MXPA02001231A (en) | Methods and compositions for detecting larval taenia solium. | |
EP1130030A1 (en) | Human erythroid differentiation related factor | |
Apostolidis et al. | The peptide loop consisting of amino acids 139–157 of human granzyme B (fragmentin 2) contains an immunodominant epitope recognized by the mouse | |
AU2003267876A1 (en) | Aspartyl protease inhibitor as a nematode allergen | |
Ito et al. | Screening of peptides that inhibit bacterial binding to fibronectin using combinatorial peptide libraries | |
JP2006180704A (en) | New protein and application thereof | |
NZ521434A (en) | Novel allergen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21558/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2309534 Country of ref document: CA Ref country code: CA Ref document number: 2309534 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-1963 Country of ref document: CZ |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998965715 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09555183 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998965715 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-1963 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998965715 Country of ref document: EP |